CDKN3 Inhibitors

CDKN3 inhibitors, as listed above, are primarily compounds that indirectly affect the activity of CDKN3 by modulating cell cycle regulation, CDK activity, or related signaling pathways. CDKN3 regulates the cell cycle by dephosphorylating and activating CDK2, which is crucial for the G1/S transition. The main approach to indirectly inhibiting CDKN3 involves targeting CDKs, particularly CDK2, which is directly regulated by CDKN3. Compounds like Palbociclib, Roscovitine, Olomoucine, Purvalanol A, Dinaciclib, Seliciclib, Milciclib, SNS-032, AT7519, Ribociclib, and Abemaciclib are inhibitors of various CDKs. By inhibiting CDKs, these compounds can indirectly influence CDKN3's role in cell cycle regulation. Flavopiridol is a broad-spectrum CDK inhibitor that can impact multiple CDKs and, by extension, may affect CDKN3's function. By altering the activity of CDK2, these inhibitors can indirectly modulate the role of CDKN3 in cell cycle control.